Benazepril, treatment for patients with chronic kidney disease Review article
Article Sidebar
Published:
Apr 13, 2010
Keywords:
benazepril, chronic kidney disease, proteinuria, hyperkaliemia
Main Article Content
Abstract
Aggressive treatment of hypertension slows the progression of chronic kidney disease (CKD). Inhibition of the renin-angiotensin-aldosterone system (RAAS) is a key strategy in treating hypertension and cardiovascular and renal diseases. Angiotensin-converting enzyme inhibitors (ACEi) are particularly beneficial in CKD patients with proteinuria of more than 1 g/day. However, ACEi are associated with an increased risk of serum creatinine rise and hyperkalemia. Increases in serum creatinine levels up to 30% should not lead to its discontinuation. Drug selection and dose adjustment according to CKD must be implemented durin ACEi treatment. Low potassium diet and diuretics can be used to avoid hyperkaliemia.
Article Details
How to Cite
Małecki , R. (2010). Benazepril, treatment for patients with chronic kidney disease. Medycyna Faktow (J EBM), 3(1(6), 61-67. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2616
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Cockcroft D.W., Gault M.H.: Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31-41.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39 (2 Suppl. 1): S1-S266.
3. Jungers P., Massy Z.A., Khoa T.N.: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients. A prospective study. Nephrol. Dial. Transplant. 1997; 12: 2597-2602.
4. Foley R.N., Parfrey P.S., Sarnak M.J.: Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998; 9: S16-S23.
5. Kirby T.: Screening for chronic kidney disease shows promise. Lancet 2010; 375: 1240-1241.
6. James M.T., Hemmelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309.
7. Wolf G., Butzmann U., Wenzel U.O.: The renin-angiotensin system and progresion of renal disease: from hemodynamics to cell biology. Nephron. Physiol. 2003; 93: 3-13.
8. De Cesaris R., Ranieri G., Andriani A., Lamontanara G.: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with Diabetes. Clin. Pharm. Therap. 1996; 60: 472-478.
9. Campbell R.C., Ruggenenti P., Remuzzi G.: Halting the progression of chronic nephropathy. J. Am. Soc. Nephrol. 2002; 13: 190-5.
10. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. 2003; 138: 917.
11. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med. 2000; 160(5): 685-693.
12. Pitt B., Bakris G., Ruilope L.M. et al.: Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118(16): 1643-1650.
13. Massie B.M., Armstrong P.W., Cleland J.G., Horowitz J.D., Packer M., Poole-Wilson P.A. et al.: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161(2): 165-71.
14. de Zeeuw D., Lambers-Heerspink H.: Drug Dosing for Renoprotection: Maybe It’s Time for a Drug Efficacy-Safety Score? J. Am. Soc. Nephrol. 2009; 20: 688-689.
15. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. 2003; 138: 917.
16. Pelliccia F.: ACE-inhibitor of proven efficacy. MEDICI OGGI – EXTRACTS 2007; XI: 4.
17. Farmakologia inhibitorów konwertazy angiotensyny. W: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Januszewicz A., Januszewicz W., Rużyłło W. (red.). Medycyna Praktyczna, Kraków 2005: 89-106.
18. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14 (supl. 4): IV79-IV82.
19. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334(15): 939-945.
20. Locatelli F., Del Vecchio L.: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol. Dial. Transplant. 1999; 14: 1360-1364.
21. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006; 354: 131-140.
22. Hou F.F., Xie D., Zhang X. et al.: L Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 2007; 18(6): 1889-98.
23. Jamerson K., Weber M.A., Bakris G.L., for the ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
24. Bakris G.L., Sarafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375(9721): 1173-81.
25. Bakris G.L., Toto R.D., McCullough P.A. et al.: On behalf of the GUARD Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-1309.
26. Rutkowski P., Tylicki L., Renke M. et al.: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260.
27. Ruggenenti P., Remuzzi G.: Proteinuria: Is the ONTARGET renal substudy actually off-target? Nat. Rev. Nephrol. 2009; 5: 436-437.
28. Hebert L.A.: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006; 354: 189-191.
29. Wolf G., Ritz E.: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005; 67: 798-812.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39 (2 Suppl. 1): S1-S266.
3. Jungers P., Massy Z.A., Khoa T.N.: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients. A prospective study. Nephrol. Dial. Transplant. 1997; 12: 2597-2602.
4. Foley R.N., Parfrey P.S., Sarnak M.J.: Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998; 9: S16-S23.
5. Kirby T.: Screening for chronic kidney disease shows promise. Lancet 2010; 375: 1240-1241.
6. James M.T., Hemmelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309.
7. Wolf G., Butzmann U., Wenzel U.O.: The renin-angiotensin system and progresion of renal disease: from hemodynamics to cell biology. Nephron. Physiol. 2003; 93: 3-13.
8. De Cesaris R., Ranieri G., Andriani A., Lamontanara G.: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with Diabetes. Clin. Pharm. Therap. 1996; 60: 472-478.
9. Campbell R.C., Ruggenenti P., Remuzzi G.: Halting the progression of chronic nephropathy. J. Am. Soc. Nephrol. 2002; 13: 190-5.
10. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. 2003; 138: 917.
11. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med. 2000; 160(5): 685-693.
12. Pitt B., Bakris G., Ruilope L.M. et al.: Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118(16): 1643-1650.
13. Massie B.M., Armstrong P.W., Cleland J.G., Horowitz J.D., Packer M., Poole-Wilson P.A. et al.: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161(2): 165-71.
14. de Zeeuw D., Lambers-Heerspink H.: Drug Dosing for Renoprotection: Maybe It’s Time for a Drug Efficacy-Safety Score? J. Am. Soc. Nephrol. 2009; 20: 688-689.
15. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. 2003; 138: 917.
16. Pelliccia F.: ACE-inhibitor of proven efficacy. MEDICI OGGI – EXTRACTS 2007; XI: 4.
17. Farmakologia inhibitorów konwertazy angiotensyny. W: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Januszewicz A., Januszewicz W., Rużyłło W. (red.). Medycyna Praktyczna, Kraków 2005: 89-106.
18. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14 (supl. 4): IV79-IV82.
19. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334(15): 939-945.
20. Locatelli F., Del Vecchio L.: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol. Dial. Transplant. 1999; 14: 1360-1364.
21. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006; 354: 131-140.
22. Hou F.F., Xie D., Zhang X. et al.: L Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 2007; 18(6): 1889-98.
23. Jamerson K., Weber M.A., Bakris G.L., for the ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
24. Bakris G.L., Sarafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375(9721): 1173-81.
25. Bakris G.L., Toto R.D., McCullough P.A. et al.: On behalf of the GUARD Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-1309.
26. Rutkowski P., Tylicki L., Renke M. et al.: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260.
27. Ruggenenti P., Remuzzi G.: Proteinuria: Is the ONTARGET renal substudy actually off-target? Nat. Rev. Nephrol. 2009; 5: 436-437.
28. Hebert L.A.: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006; 354: 189-191.
29. Wolf G., Ritz E.: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005; 67: 798-812.